Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date08 Sep 1986 |
Phase 2a trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy. - GBS-01 Phase IIa
100 Clinical Results associated with Kracie Pharma Ltd.
0 Patents (Medical) associated with Kracie Pharma Ltd.
100 Deals associated with Kracie Pharma Ltd.
100 Translational Medicine associated with Kracie Pharma Ltd.